書誌事項
- タイトル別名
-
- Efficacy of Prophylactic Intravesical Mitomycin C in Patients with Non-Muscle-Invasive Bladder Cancer
- キンソウ ヒシンジュンセイ ボウコウガン ニ タイスル サイハツ ヨボウ モクテキ Mitomycin C ボウコウ ナイ チュウニュウ リョウホウ ノ ケントウ
この論文をさがす
抄録
Intravesical chemotherapy is beneficial for patients with non-muscle-invasive bladder cancer (NMIBC), but optimal drug and regimen selection can be controversial. Mitomycin C (MMC) is commonly used as adjuvant treatment for NMIBC. We retrospectively evaluated the outcomes of 73 patients with NMIBC who were treated with weekly doses of low-dose MMC (20 mg ; n=28 ; 38.4%) orhigh-dose MMC (40 mg ; n=45 ; 61.6%) for6 weeks each, at ourhospital between 2001 and 2010. Treatment outcomes were examined by Kaplan‒Meier analysis with log-rank tests. Patients in the high-dose group showed greater recurrent-free survival (61.3%) at 2 years than did patients in the low-dose group (32.6%) (P<0.05). We also found that a single early dose of pirarubicin following transurethral resection of bladder tumor improved MMC efficacy in the high-dose group. The high-dose group had a somewhat higher incidence of dysuria, urinary frequency and drug eruption, but the difference was not significant.
収録刊行物
-
- 泌尿器科紀要
-
泌尿器科紀要 60 (8), 375-379, 2014-08
泌尿器科紀要刊行会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1050845760726935680
-
- NII論文ID
- 120005468368
-
- NII書誌ID
- AN00208315
-
- ISSN
- 00181994
-
- HANDLE
- 2433/189543
-
- NDL書誌ID
- 025704001
-
- 本文言語コード
- ja
-
- 資料種別
- departmental bulletin paper
-
- データソース種別
-
- IRDB
- NDL
- CiNii Articles